Skip to main content
. Author manuscript; available in PMC: 2009 May 8.
Published in final edited form as: Circulation. 2008 Jun 2;117(24):3099–3108. doi: 10.1161/CIRCULATIONAHA.108.767673

Figure 8.

Figure 8

Fstl1 protects against myocardial ischemia/reperfusion injury in vivo. A, Western blot analysis of serum proteins from mice after the intravenous delivery of the indicated adenoviral vector. Sera were collected and analyzed 5 days after adenovirus delivery. Serum Fstl1 level was markedly increased by administration of Ad-Fstl1. B, Representative photographs of heart sections stained with Evans blue and 2-3-5-triphenyl tetrazolium chloride to detect the infarction zone resulting from 30 minutes of ischemia and 24 hours of reperfusion. Ischemia/reperfusion injury was performed 5 days after adenoviral injection. C, Quantification of infarction size of each experimental group (n=10 for Ad-βgal group; n=7 for Ad-Fstl1 group). *P<0.05 compared with Ad-βgal-injected group. D, Representative fluorescent images of heart sections stained with TUNEL (green), sarcomeric actin (red), and DAPI (blue). Scale bar=100 μm. E, Quantification of TUNEL-positive myocyte number showed that administration of Ad-Fstl1 decreased apoptosis (n=3 for each group). *P<0.01 compared with Ad-βgal-injected group.